Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
View Patent ↗The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.
1. A method of treating a patient suffering from a bleeding disorder, wherein the method comprises administering to the patient a pharmaceutical composition that comprises an antibody against the A3-C1 region of Factor VIII and at least one selected from the group consisting of a physiologically acceptable excipient, carrier, diluent, and stabilizator.
2. The method according to claim 1 , wherein the bleeding disorder is Haemophilia A, von Willebrand's disease, or a temporary impairment of blood coagulation during or after a surgical procedure.
3. The method according to claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence according to SEQ ID NO: 23 and a heavy chain comprising the amino acid sequence according to SEQ ID NO: 21.
4. The method according to claim 1 , wherein the antibody is KM33 antibody (SEQ ID NO: 26).
5. The method according to claim 1 , wherein the pharmaceutical composition comprises an antibody against the C1 domain of the Factor VIII.